Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 16, 2026 09:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual Meeting

SAN DIEGO, April 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced...
April 16, 2026 08:53 ET | Source: Achieve Life Sciences

Achieve Life Sciences Announces Up to $354 Million Private Placement

$180 Million Financing Upfront with Up to an Additional $174 Million from Warrants Exercisable Within 20 Days of FDA Approval Transaction led by Frazier Life Sciences, TPG Life Sciences Innovations,...
April 16, 2026 08:45 ET | Source: International Myeloma Foundation

Blood Cancer Patients and Their Supporters Cycle Across Iceland to Raise Funds and Awareness for Multiple Myeloma and the International Myeloma Foundation’s Research

STUDIO CITY, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announces its 3rd annual Iceland Cycling Expedition, taking place August 18-24, 2026, where...
April 16, 2026 08:35 ET | Source: NANO-X IMAGING LTD

Nanox.ARC X Digital Advanced 3D imaging built for access and powered by innovation Wins 2026 Red Dot Award for Product Design

International Red Dot Jury recognizes Nanox.ARC X for design excellence that brings advanced 3D tomosynthesis imaging into a wider range of clinical settings PETACH TIKVA, ISRAEL - 16 April, 2026 -...
April 16, 2026 07:30 ET | Source: Paratek Pharmaceuticals, Inc.

Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2026

Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2026
April 16, 2026 07:25 ET | Source: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting

MELBOURNE, Australia and SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
April 16, 2026 07:10 ET | Source: MeiraGTx

MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

Company entered into an asset purchase agreement with Johnson & Johnson (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis...
April 16, 2026 07:00 ET | Source: Nula Therapeutics

Nula Therapeutics Launches with up to $20 Million ARPA-H Award to Advance a New Class of Medicines Targeting the Nuclear Envelope of Cells

Nula Therapeutics Launches with up to $20 Million ARPA-H Award to Advance a New Class of Medicines Targeting the Nuclear Envelope of Cells
April 16, 2026 07:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function

BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human,...
April 16, 2026 07:00 ET | Source: Metagenomi Therapeutics, Inc.

Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency

Metagenomi Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Editing Efficiency